Adjuvant treatment for high risk melanoma. Where are we now?
The survival rate for stage 3 and 4 melanoma is very poor. In the absence of effective treatments for metastatic disease focus has shifted to the adjuvant setting. While we are now able to identify those who are at high risk of recurrence the role of adjuvant systemic treatment in these individuals...
Bewaard in:
| Hoofdauteurs: | , , |
|---|---|
| Formaat: | Boek |
| Gepubliceerd in: |
Frontiers Media S.A.,
2011-12-01T00:00:00Z.
|
| Onderwerpen: | |
| Online toegang: | Connect to this object online. |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|
Internet
Connect to this object online.3rd Floor Main Library
| Plaatsingsnummer: |
A1234.567 |
|---|---|
| Kopie 1 | Beschikbaar |